A Critical Deadline for CureVac Shareholders

The contest for control is over. BioNTech has emerged victorious, securing a dominant stake. For investors holding CureVac stock, however, the story is far from concluded. In fact, a period of urgent action has begun. Remaining passive now could lead to significant and avoidable financial penalties due to impending tax complications. Shareholders must navigate the next fortnight carefully to sidestep a costly trap.

Certainty arrived on Wednesday morning: the consolidation of Germany's mRNA sector is effectively complete. BioNTech confirmed it has successfully crossed the minimum acceptance threshold and now commands 81.74 percent of CureVac's outstanding shares. This cures the fate of the Tübingen-based firm as an independent listed entity. While the strategic acquisition is settled at the corporate level, a strict clock is now ticking for remaining retail investors.

Navigating the Tax Implications

BioNTech has immediately initiated a subsequent offering period, which concludes strictly on December 18, 2025. This is not a mere formality but a serious financial warning. Shareholders who do not tender their holdings within this final window risk being swept into a tax-inefficient compulsory restructuring.

Should investors sell immediately? Or is it worth buying CureVac?

Specifically, investors who simply wait for the automatic allocation of BioNTech shares face a potential 15 percent Dutch withholding tax on the proceeds. This unfavorable outcome can typically be avoided if shareholders proactively accept the exchange offer now. Given that banks and brokers often require several days to process instructions, immediate action is strongly advised.

The Final Chapter for CureVac Stock

On the trading floor, speculative momentum has evaporated. The share price is no longer driven by pipeline potential or financial performance; it is now tethered almost exclusively to BioNTech's fixed exchange ratio. Closing at 4.42 euros, the stock has lost any independent valuation basis, acting merely as a placeholder until the inevitable delisting.

The focus has decisively shifted from biotech research to procedural bureaucracy. BioNTech is expected to finalize the integration and absorb the remaining assets by the first quarter of 2026, at which point the CureVac ticker will disappear from the trading screen. For investors, the message is clear: the time for speculation has passed. The priority now is executing a clean exit without incurring unnecessary tax liabilities.